/
ATHE
$4.89+$0.07 (+1.45%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$87.4M
18M shares
52-week range
$2.66 – $7.00
51% from low
Exchange
NASDAQ
ADRC
Borrow rate
6.75%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-16.51
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $201.2K | $108.5K | $0 | $4.3M | $5.1M | $3.9M | $4.0M | $5.4M |
| Cost of revenue | $21.8K | $29.7K | $112.4K | $360.0K | $364.7K | $285.1K | $214.3K | $127.5K |
| Gross profit | $179.4K | $78.8K | −$112.4K | $4.0M | $4.8M | $3.6M | $3.8M | $5.3M |
| Gross margin | 89.2% | 72.6% | — | 91.7% | 92.9% | 92.7% | 94.7% | 97.7% |
| R&D | $6.7M | $13.0M | $10.1M | $12.3M | $14.7M | $13.2M | $18.6M | $14.4M |
| Operating income | −$7.8M | −$12.7M | −$10.4M | −$15.2M | −$15.5M | −$14.6M | −$19.6M | −$14.6M |
| EBITDA | −$11.4M | −$12.8M | −$13.3M | −$15.2M | −$17.4M | −$14.6M | −$19.6M | −$14.6M |
| Net income | −$8.3M | −$12.0M | −$10.1M | −$15.3M | −$12.8M | −$13.8M | −$19.1M | −$12.1M |
| Net margin | -4108.8% | -11020.8% | — | -352.8% | -250.7% | -352.5% | -475.8% | -223.4% |
| EPS (diluted) | -9.30 | -11.64 | -6.48 | -5.40 | -3.18 | -3.42 | -3.12 | -1.14 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4M | $-0.49 | $-0.49–$-0.49 | 1 |
| 2027 | $4M | $-0.56 | $-0.56–$-0.56 | 1 |
| 2028 | $6M | $-0.56 | $-0.56–$-0.56 | 1 |
| 2029 | $11M | $-0.73 | $-0.73–$-0.73 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Alterity Therapeutics Limited American Depositary Shares
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
www.alteritytherapeutics.com- Employees
- 9
- IPO / List date
- Mar 4, 1992
Held by traders on TradeandTell
No one on the platform currently holds ATHE.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ATHE as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-01-09 | 1-for-10reverse |
| 2016-03-24 | 1-for-6reverse |
Recent trades on TradeandTell
No one on the platform has traded ATHE yet.
